Bone and soft tissue sarcomas, tumors of the skinBone and soft tissue sarcomas, tumors of the skinСаркомы костей, мягких тканей и опухоли кожи2219-46142782-3687Publishing House ABV Press57SOFT TISSUE SARCOMASСАРКОМЫ МЯГКИХ ТКАНЕЙNew in the classification of soft tissue sarcomasНовое в классификации сарком мягких тканейManikayloA. E.МаникайлоА. Е.
Russian Federation
7717271@mail.ruBurovD. A.БуровД. А.
Russian Federation
BokhyanB. Y.БохянБ. Ю.
Russian Federation
KharatishviliT. K.ХаратишвилиТ. К.
Russian Federation
FSBI «N.N. Blokhin National Medical Research Center of Oncology» of the Ministry of Health of RussiaФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России16042019111152116042021Copyright ©; 2019, Manikaylo A.E., Burov D.A., Bokhyan B.Y., Kharatishvili T.K.Copyright ©; 2019, Маникайло А.Е., Буров Д.А., Бохян Б.Ю., Харатишвили Т.К.2019Manikaylo A.E., Burov D.A., Bokhyan B.Y., Kharatishvili T.K.Маникайло А.Е., Буров Д.А., Бохян Б.Ю., Харатишвили Т.К.https://creativecommons.org/licenses/by/4.0https://sarbon.abvpress.ru/jour/article/view/57

The purpose of this work is to present in Russia a modern classification for various forms of soft tissue sarcoma. Also present possible genetic aberrations for all types of tumors.

Целью данной работы является представление в России современной классификации для различных форм саркомы мягких тканей. А также обозначить возможные генетические аберрации для всех типов опухоли. Это в последующем может помочь в определении тактики дальнейшего лечения.

TNM-классификацияTNM-classificationstagingclassification of the World Health Organizationстадированиеклассификация Всемирной организации здравоохранениясаркомаопухольмягкие тканиКаприн АД, Старинский ВВ, Петрова ГВ. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена, филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2018:250.Буров ДА, Бохян БЮ, Петроченко НС, Харатишвили ТК, Агаев ДК. Разработка системы индивидуального прогнозирования появления рецидива сарком мягких тканей. Саркомы костей, мягких тканей и опухоли кожи. М.: «Фармарус Принт Медиа». 2017;(3):3-7.Бохян БЮ, Буров ДА, Петроченко НС, Харатишвили ТК, Агаев ДК. Анализ факторов риска появления рецидивов сарком мягких тканей на основе клинико-морфологических характеристик опухоли. Саркомы костей, мягких тканей и опухоли кожи. М.: «Фармарус Принт Медиа». 2018;(1):39-46.Феденко АА. Стратегия лекарственного лечения сарком мягких тканей. Автореферат дисс. д-ра мед. наук. М., 2016. Доступно на сайте: http://docme.ru/ghR6.Lucchesi C, Khalifa E, Laizet Y et al. Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas: Insights for Personalized Therapy. JAMA Oncol. 2018;4(10):1398-1404. PMID: 29801054.Amin MB, Edge SB, Greene FL et al. AJCC Cancer Staging Manual, 8th edition. New York: Springer; 2017.Брайерл ДжД, Господарович МК, Виттекинд К. TNM Классификация злокачественных опухолей. Пер. с англ. Е.А. Дуброван. Логосфера. 2018:344.Version 2.2018, 03/27/18 © National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.Pfeifer JD, Hill DA, O’Sullivan MJ, Dehner LP. Diagnostic gold standard for soft tissue tumours: morphology or molecular genetics? Histopathology. 2000;37:485-500. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11122430.Sorensen PHB, Lynch JC, Qualman SJ et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group. J Clin Oncol. 2002;20:2672-2679. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12039929.Dickson MA, Tap WD, Keohan ML et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well- differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013;31:2024-2028. Available at: http://www. ncbi.nlm.nih.gov/pubmed/23569312.Dickson MA, Tap WD, Keohan ML et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified liposarcoma [abstract]. ASCO Meeting Abstracts. 2013;31:10512. Available at: http://meeting.ascopubs.org/cgi/ content/abstract/31/15_suppl/10512.Cassier PA, Kantor G, Bonvalot S et al. Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/ well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) study. Ann Oncol. 2014;25:1854-1860. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24914041.Billing V, Mertens F, Domanski HA, Rydholm A. Deep-seated ordinary and atypical lipomas: histopathology, cytogenetics, clinical features, and outcome in 215 tumours of the extremity and trunk wall. J Bone Joint Surg Br. 2008;90:929-933. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18591605.Sommerville SMM, Patton JT, Luscombe JC et al. Clinical outcomes of deep atypical lipomas (well-differentiated lipoma-like liposarcomas) of the extremities. ANZ J Surg. 2005;75:803-806. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/16173997.Lazar AJ, Tuvin D, Hajibashi S et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518-1527. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18832571.Domont J, Salas S, Lacroix L et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer. 2010;102:1032-1036. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20197769.Le Guellec S, Soubeyran I, Rochaix P et al. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Mod Pathol. 2012;25:1551-1558. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22766794.Colombo C, Miceli R, Lazar AJ et al. CtNnB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: An independent, multicenter validation study. Cancer. 2013;119:3696-3702. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23913621.Mullen JT, DeLaney TF, Rosenberg AE et al. beta-Catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist. 2013;18:1043-1049. Available at: http://www.ncbi. nlm.nih.gov/pubmed/23960186.Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006;101:385-398. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/16454848.Half E, Bercovich D, Rozen P Familial adenomatous polyposis. Orphanet J Rare Dis. 2009;4:22. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/19822006.Nieuwenhuis MH, Lefevre JH, Bulow S et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum. 2011;54:1229-1234. Available at: http://www ncbi.nlm.nih.gov/pubmed/21904137.Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53:245-266. Available at: http://www. ncbi.nlm.nih.gov/pubmed/18312355.Janeway KA, Kim SY, Lodish M et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA. 2011;108:314-318. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/21173220.Pantaleo MA, Astolfi A, Urbini M et al. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST Eur J Hum Genet. 2014;22:32-39. Available at: http://www. ncbi.nlm.nih.gov/pubmed/23612575.Agaimy A, Terracciano LM, Dirnhofer S et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol. 2009;62:613-616. Available at: http://www.ncbi. nlm.nih.gov/pubmed/19561230.Oudijk L, Gaal J, Korpershoek E et al. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Mod Pathol. 2013;26:456-463. Available at: http://www.ncbi. nlm.nih.gov/pubmed/23174939.Korf BR. Neurofibromatosis. Handb Clin Neurol. 2013;111:333-340. Available at: http://www.ncbi.nlm.nih. gov/pubmed/23622184.Guillou L, Benhattar J, Bonichon F et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol. 2004;22:4040-4050. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/15364967.Ladanyi M, Antonescu CR, Leung DH et al. Impact of SYTSSX fusion type on the clinical behavior of synovial sarcoma: a multi- institutional retrospective study of 243 patients. Cancer Res. 2002;62:135-140. Available at: http://www.ncbi.nlm.nih. gov/pubmed/11782370.Kleinerman RA, Tucker MA, Abramson DH et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst. 2007;99:24-31. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17202110.Kleinerman RA, Schonfeld SJ, Tucker MA. Sarcomas in hereditary retinoblastoma. Clin Sarcoma Res. 2012;2:15. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23036192.Brems H, Beert E, de Ravel T, Legius E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis typeLancet Oncol. 2009;10:508-515. Available at: http://www. ncbi.nlm.nih.gov/pubmed/19410195.Hill DA, O’Sullivan MJ, Zhu X et al. Practical application of molecular genetic testing as an aid to the surgical pathologic diagnosis of sarcomas: a prospective study. Am J Surg Pathol. 2002;26:965-977. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/12170083.Italiano A, Di Mauro I, Rapp J et al. Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study. Lancet Oncol. 2016;17:532-538. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/26970672.Antonescu CR, Tschernyavsky SJ, Decuseara R et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001;7:3977-3987. Available at: http://www.ncbi.nlm.nih. gov/pubmed/11751490.Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology. 2006;48:13-21. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/16359533.Penel N, Grosjean J, Robin YM et al. Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases. Sarcoma. 2008:459386. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/18497869.Li FP, Fraumeni JF Jr., Mulvihill JJ et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358-5362. Available at: http://www.ncbi.nlm.nih. gov/pubmed/3409256.Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233-1238. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/1978757.Nichols KE, Malkin D, Garber JE et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev. 2001;10:83-87. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11219776.Ognjanovic S, Olivier M, Bergemann TL, Hainaut P Sarcomas in TP53 germline mutation carriers. Cancer. 2012;118:1387-1396. Available at: http://www.ncbi.nlm.nih. gov/pubmed/21837677.